Phase 1 Trial of M032 IL-12 Producing HSV Oncolytic Virus for Diffuse Midline Glioma

This trial led by MD Anderson Cancer Center evaluates a single intratumoral injection of M032, an IL-12 producing HSV oncolytic virus, in pediatric and adult patients with diffuse midline glioma following standard radiation therapy. The single-arm design enrolls independent supratentorial and pontine cohorts to assess safety and determine the recommended Phase 2 dose, marking a first-in-human exploration of intratumoral immunovirotherapy.